PATENT CLAIM ANALYSIS

Application Number: 15903662
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "317000"]

Abstract:
This invention relates to improvements in therapeutic neurological and neuropsychic treatments using acetylcholinesterase inhibitors. More specifically, the invention enables the effects of the reversible acetylcholinesterase inhibitor donepezil to be potentiated by certain molecules, referred to here as connexin-blocking agents. Said connexin-blocking agent is preferably meclofenamic acid.

Claim (Index 22):
A method of potentiating the effect of donepezil or a pharmaceutical salt thereof in patients suffering from cognitive disorders which comprises which comprises coadministering a connexin-blocking agent with said donepezil or a pharmaceutical salt thereof, wherein said connexin-blocking agent is mefloquine.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 88.0
- Lexical Diversity: 1.2439
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14479614', '14861169', '12758631', '14218083', '16320949']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7598506276437673
- 35 USC 102 Novelty (BERT): 0.4951616103150643
- Combined Prediction Score: 0.7333817259108971
- Mean Citation Score: 200.030694
- Max Citation Score: 205.81007
- Similarity Product: 140.65112424561025

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test